Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc. (RVMD), executed a significant sale of company stock on June 17, 2026. Horn sold 60,400 shares at an average price of $160.17 per share, realizing approximately $9.67 million from the transaction.
This sale follows a series of other stock dispositions by Horn in mid-June, totaling over 90,000 shares across multiple transactions. While insider sales can be driven by various personal financial considerations such as tax planning or portfolio diversification, they are closely monitored by market participants.
Revolution Medicines, Inc. is a clinical-stage oncology company focused on developing novel therapies. The company's stock performance and future prospects are subject to ongoing clinical trial results and regulatory developments.